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Abstract
Background: Breakthrough viridans streptococcal bacteremia (VSB) in patients with hematological malignancy
receiving levofloxacin prophylaxis is a major blood stream infection (BSI) occurring during febrile neutropenia.
However, clinical data focused on VSB in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients are
lacking.
Methods: The medical records of allo-HSCT recipients who received oral levofloxacin prophylaxis between January
2011 and August 2013 at Toranomon Hospital were reviewed to evaluate breakthrough VSB. Stored viridans
streptococcal (VGS) species were identified by using sodA gene sequencing, and were assessed for drug
susceptibility.
Results: Among the 184 allo-HSCT recipients on levofloxacin prophylaxis, 28 (15.2 %) experienced breakthrough
VSB. All of the 28 recipients with VSB were treated with a cefepime-based or piperacillin/tazobactam-based
regimen. The susceptibility rates of the VGS strains for levofloxacin, cefepime, piperacillin/tazobactam, meropenem,
and vancomycin were 0 %, 95 %, 100 %, 100 %, and 100 %, respectively. Both the MIC50 (minimum inhibitory
concentration) and the MIC90 of ceftazidim (0.5 μg/mL and 2 μg/mL, respectively) were higher than the MIC90 of
all the other anti-pseudomonal beta-lactams (APBLs). Only 1 VGS strain had a penicillin MIC ≥ 2 μg/mL by the
Etest (3.6 %). There were no cases with acute respiratory distress syndrome (ARDS) that was associated with VSB,
although the rate of viridans group streptococcal shock syndrome was high (26 %). The crude 30-day mortality
rate in the VSB group (10.7 %) did not differ significantly from that in the BSI without VSB group (9.3 %) or
non-BSI group (7.0 %) (P = 0.77). Also, VSB was not a risk factor for all-cause mortality up to 60 days following
allo-HSCT (P = 0.43).
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Conclusions: APBL with increased anti-VGS activity (APBL-VA) monotherapy would typically be optimal for
treating the VGS strains in this setting. Indication of adding an empiric anti-gram-positive agent to APBL-VA for
treating VSB should depend on local factors, such as the susceptibility results. In addition, breakthrough VSB is
probably not a major cause of death in allo-HSCT settings, where beta-lactam non-susceptible VGS and the ARDS
are rare.
Keywords: Allogeneic hematopoietic stem cell transplantation, Febrile neutropenia, Levofloxacin prophylaxis,
Levofloxacin breakthrough, Ceftazidime, Viridans streptococcus
Background
Fluoroquinolone prophylaxis should be considered for
high-risk patients with prolonged and profound neutro-
penia [1]. Allogeneic hematopoietic stem cell transplant
(allo-HSCT) recipients are the primary constitutes of
this high-risk group. Among them, breakthrough blood
stream infection (BSI) on fluoroquinolone prophylaxis
has been reported [2–5]. Some allo-HSCT recipients
have also been reported to have breakthrough BSI on
levofloxacin prophylaxis, and viridans group strepto-
coccus (VGS) is one of the causative organisms [2, 3].
Additionally, VGS is a major causative organism of
febrile neutropenia (FN) in cancer patients [6–10]. The
2010 Infectious Diseases Society of America (IDSA) FN
guideline recognizes that anti-pseudomonal beta-lactam
(APBL) antibiotics currently employed as empiric
monotherapy in FN generally have good in vitro anti-
VGS activity [1]. The APBLs with increased anti-VGS
activity (APBL-VAs) recommended by the guideline are
cefepime, piperacillin/tazobactam, and antipseudomo-
nal carbapenems [1], and as such anti-gram-positive
agents (AGPAs), including vancomycin, linezolid, or
daptomycin, are not routinely recommended when viri-
dans streptococcal bacteraemia (VSB) is suspected [1].
However, it is not clear whether this recommendation
is optimal for all clinical settings, including the allo-
HSCT setting. A recent report described that in vitro
resistance to the APBL-VAs was observed in VGS iso-
lates with a penicillin minimum inhibitory concentra-
tion (MIC) measured by Etest of ≥ 2 μg/mL [11].
Therefore, the clinical criteria that can assist with the
targeted use of AGPAs only for the VSB that caused by
VGS strains with penicillin MIC ≥ 2 μg/mL has been
suggested [11]. On the other hand, some clinical cen-
ters choose prophylactic vancomycin for high-risk pa-
tients to prevent infection caused by gram-positive
cocci such as VGS [12, 13]. A report from United States
described that the mortality rate of VSB was 21.9 % and
early administration of vancomycin was highly protect-
ive against VSB in the allo-HSCT setting [13]. However,
the allo-HSCT recipients did not receive any prophy-
lactic antimicrobial agents such as fluoroquinolone, and
were initially treated by combination of ticarcillin/
clavulanic acid and amikacin during neutropenia [13].
These findings may not extend to current allo-HSCT
settings.
This is the first report to describe the characteristics
of VSB and therapeutic strategies for the VSB in allo-
HSCT recipients with FN who received levofloxacin
prophylaxis in the era of APBL-VAs.
Methods
Study patients
A retrospective analysis of VSBs among allo-HSCT re-
cipients (age, ≥16 years) who received standard prophy-
laxis with 500 mg/day oral levofloxacin was conducted
between January 2011 and August 2013 at the Torano-
mon Hospital (890 beds; Tokyo, Japan). The medical
and microbiological records of the recipients under
levofloxacin prophylaxis during the study period were
reviewed. Our standard strategy of levofloxacin prophy-
laxis for allo-HSCT recipients was introduced in Janu-
ary 2011 comprises following three major policies: (1)
500 mg/day oral levofloxacin prophylaxis started before
day −7 (7 days before allo-HSCT); (2) levofloxacin
prophylaxis stopped at the first episode of FN and
changed to another antimicrobial regimen immediately
after obtaining ≥ 2 sets of blood cultures; and (3) con-
tinuation of levofloxacin prophylaxis until neutrophil
engraftment in the absence of any FN episodes. Neu-
trophil engraftment was defined as the first of 3 con-
secutive days with ANC (absolute neutrophil count)
of ≥ 500cells/μL. A central venous access device was
inserted before conditioning was started. All recipients
received antifungal agents and acyclovir for prophy-
laxis. Trimethoprim-sulfamethoxazole was given from
day −7 through day −2 for Pneumocystis prophylaxis.
Urine, stool, nasal, and pharyngeal swabs were col-
lected from each allo-HSCT recipient for methicillin-
resistant Staphylococcus aureus (MRSA) colonization
screening within 3 months before allo-HSCT. Stool
samples were also collected for vancomycin-resistant
enterococci (VRE) colonization screening at the same
time. All the cord blood transplant recipients received
single cord blood during the study period.
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This study was approved by the Human Ethics Review
Committee of Toranomon Hospital.
Definitions
Breakthrough VSB was defined as the presence of at
least a single positive result of blood culture for VGS in
a sample drawn from a patient at the first episode of FN
under levofloxacin prophylaxis. The definition of VSB
was the same as the previous study in the allo-HSCT
setting [13].
The definition of FN included criteria for body
temperature and neutrophil count: Body temperature ≥
37.5 °C measured at the axially fossa, according to rou-
tine practice in Japan [14]; and ANC <500 cells/μL or
ANC that decreased to <500 cells/μL during the 48 h
following the occurrence of fever [1].
For disease status, all hematological disorders were
defined as either standard risk, or high risk [15]. Con-
ditioning regimens were classified based on the report
by the Center for International Blood and Marrow
Transplant Research [16]. Myeloid malignancy con-
tains acute myeloid leukemia (AML), myelodysplastic
syndrome (MDS), MDS overt AML, and chronic mye-
logenous leukemia. The recipients with prior history of
allogeneic hematopoietic stem cell transplantation (PH-
allo-HSCT) indicates the recipients who received allo-
geneic hematopoietic stem cell transplantation 2 or
more times. Coagulase negative staphylococci, Coryne-
bacterium species, unidentified gram positive cocci, and
unidentified gram positive cocci were considered con-
taminants unless they were cultured from ≥ 2 separate
blood culture bottles. Co-infection was defined as the
identification of ≥ 2 bacterial species in multiple blood
culture bottles of samples collected within 24 h.
Hypotension, septic shock, and acute respiratory dis-
tress syndrome (ARDS) were defined as described previ-
ously [17, 18]. Refractory hypotension was defined as
hypotension that was refractory to intravenous fluid
therapy. VGS shock syndrome was defined as monobac-
teremia of viridans streptococcus (mono VSB) with
refractory hypotension (patients who had VSB with co-
infection were excluded). Invasive aspergillosis was de-
fined as probable or proven invasive aspergillosis accord-
ing to the EORTC-MSG criteria [19].
Initial antimicrobial regimen at the onset of levofloxacin
breakthrough FN
Monotherapy with APBL-VA, as recommended by the
IDSA guideline, is the routine empiric initial antimicro-
bial regimen administered at the onset of FN [1]. Clini-
cians could choose any of the APBL-VAs including
cefepime, piperacillin/tazobactam, and meropenem. In
our institution, AGPAs and amikacin were not routinely
administered as a standard component of the empiric
initial antimicrobial regimen for FN.
AGPAs should be combined with the APBL-VA regi-
men for specific clinical indications, including suspected
catheter-related infection, skin or soft-tissue infection, or
severe sepsis which caused by beta-lactam-resistant
gram-positive organisms. Clinicians usually chose vanco-
mycin as the first line AGPAs, except when the recipi-
ents were allergic to vancomycin. Amikacin could be
combined with an APBL-VA regimen for suspected
severe sepsis caused by beta-lactam-resistant gram-
negative rod.
Identification of VGS and other organisms
Strains of VGS were initially identified from colony
morphology and by hemolysis and the VITEK2 system
(bioMérieux, Marcy l’Etoile, France). Additionally, the
stored VGS strains obtained from the blood samples
between August 2011 and August 2013 were also
identified to species level by examining the hetero-
geneity in streptococcal sod A gene sequences [20].
General identification of the other organisms that
cultured from blood samples to species level was
performed by VITEK2 (bioMérieux, Marcy l’Etoile,
France), or WalkAway 96 SI (Siemens Healthcare,
Deerfield, IL, USA). Helicobacter cinaedi was identi-
fied by using gyrB-targeted PCR methods. Corynebac-
terium spp. was identified into species level by RapID
CB Plus system (Remel, Lenexa, KS, USA).
Antimicrobial susceptibility
Drug susceptibility tests for levofloxacin, ceftazidime, ce-
fepime, piperacillin/tazobactam, meropenem, and vanco-
mycin were performed using microdilution methods by
the Clinical Laboratory and Standards Institute (CLSI) at
Dokkyo Medical University for the stored VGS strains
obtained from the blood samples between August 2011
and August 2013 [21]. In addition, tests for penicillin
were performed using Etest (bioMérieux, Durham, NC,
USA) for all the VGS strains obtained at Toranomon
Hospital during the entire study period. Drug suscepti-
bility breakpoints in VGS species, as established by CLSI
M100-S22, were used to categorize the MICs of the cul-
tured VGS strains [21]. Susceptibility guidelines for VGS
are not available for piperacillin/tazobactam; therefore, a
cutoff MIC of 16/4 μg/mL was chosen on a previous re-
port [11]. The breakpoint of ceftazidime has not been
defined in the CLSI M100-S22 [21].
Outcome evaluation of the febrile neutropenia
An evaluation cohort (EC) was created to evaluate the
clinical characteristics of breakthrough VSB as compared
with other groups at the first episode of FN. Among all
the study subjects, the allo-HSCT recipients who
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experienced FN were included into the EC; the recipi-
ents who successfully achieved neutrophil engraftment
without FN and continued levofloxacin prophylaxis until
neutrophil engraftment were excluded from the EC. The
EC subjects were then divided into three groups: VSB
group, consisting of recipients with VSB; BSI without
VSB group, comprising the recipients with BSI where
the causative organisms was not VGS; and the non-BSI
group, comprising recipients without BSI at the first epi-
sode of FN. Recipients with contaminant organisms cul-
tured from the blood samples included into non BSI
group.
Statistical analysis
Categorical variables were compared by the Fisher’s
exact test. Continuous variables from the different
three groups were compared by Kruskal-Wallis test.
The 30-day mortality rates and the 60-day mortality
rates after the onset of FN were estimated using
Kaplan-Meier analysis and the groups were compared
using log-rank test. The incidence of VSB was esti-
mated based on cumulative incidence curves. Com-
peting event was febrile neutropenia that associated
with non VSB causes. The groups were compared
using Gray’s test. For the multivariate analysis, vari-
ables that P-values showed ≤ 0.10 were entered into
the Fine-Gray proportional hazard model and sequen-
tially eliminated in a stepwise backward fashion until
the remaining variables were statistically significant.
Log-rank test and proportional hazard model were
used for pre-transplant variables and time dependent
variables (VSB and engraftment within 30 days fol-
lowing allo-HSCT), respectively to identify the risk
factors associated with 60 days overall mortality fol-
lowing allo-HSCT in the univariate analysis. For the
multivariate analysis, valuables that P-values showed ≤
0.10 were entered into the proportional hazard model
and sequentially eliminated in a stepwise backward
fashion until the remaining factors were statistically
significant. Significance was set at α = .05. All statis-
tical analysis was performed with EZR (Saitama
Medical Center, Jichi Medical University), which is a




Among the 184 allo-HSCT recipients who received the
standard levofloxacin prophylaxis during the study
period, 28 had breakthrough VSB. Twenty four of the 28
VGS strains (86 %) were cultured from ≥2 sets of blood
culture bottles. The cumulative incidence of the VSB
was 15.2 %. The characteristics of the 28 recipients are
shown in Table 1. Among them, 22 received cord blood
Table 1 Clinical and microbiological characteristics of 28
breakthrough VSB cases
Characteristics No.
Median age (range) 55 (20–71)
Gender
Male 15 (53.6 %)
Female 13 (46.4 %)
Hematological disorder
Myeloid malignancy
AML 3 (10.7 %)
MDS overt AML 6 (21.4 %)
MDS 8 (28.6 %)
CML 1 (3.6 %)
Lymphoid malignancy
ALL 5 (17.9 %)
NHL 1 (3.6 %)
T-PLL 1 (3.6 %)
Others
Others 3 (10.7 %)
Hematopoietic stem cell transplantation
CBT 22 (78.6 %)
rPBSCT 4 (14.3 %)
uBMT 2 (7.1 %)
Status of the patients
Nosocomial infection 28 (100 %)
Severe neutropenia (ANCs <100/pL ) 28 (100 %)
Receipt of beta-lactam in the previous 30 day 6 (21.4 %)
Clinical presentation
Median body temperature (range) (°C) 38.6 (37.5-40.6)
Acute respiratory distress syndrome 0








Cefepime 26 (92.9 %)
Piperacillin/tazobactam 2 (7.14 %)
Empiric VCM administration 4 (14.3 %)
Clinical outcome
Crude 30-day mortality 3 (10.7 %)
Crude 60-day mortality 3 (10.7 %)
Clinical presentation of mono VSB N = 19
VGS shock syndrome 5 (26 %)
AML acute myeloid leukemia, MDS myelodysplastic syndrome, CML chronic
myelogenous leukemia, ALL acute lymphoblastic leukemia, NHL non Hodgkin
lymphoma, T-PLL T-cell prolymphocytic leukemia, SAA severe aplastic anemia, CBT
cord blood transplantation , rPBSCT related peripheral blood cell transplantation,
uBMT unrelated bone marrow transplantation, ANCs absolute neutrophil counts, VCM
vancomycin, VSB viridans streptococcal bacteremia, VGS viridans group streptococcus
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stem cell transplantation, 4 received related peripheral
blood stem cell transplantation, and 2 received unrelated
bone marrow transplantation.
Microbiological characteristics of the breakthrough VSB
The clinical and microbiological characteristics of break-
through VSB are shown in Table 1. All 28 VSBs occurred
as nosocomial infections during severe neutropenia
(ANCs ≤ 100/μL) before neutrophil engraftment (from
2 days before allo-HSCT to 8 days after allo-HSCT).
Nine recipients had co-infections (32 %) caused by 10
organisms, which are listed in Table 1. Overall, 22 of the
28 VGS strains were obtained between August 2011 and
August 2013 and stored; the remaining 6 VGS strains
were obtained from January 2011 to July 2013 but not
stored. Among the 22 stored VGS strains, the causative
strains identified by sodA signature sequences were
S. mitis (14 strains), S. oralis (4 strains), S. australis
(1 strain), and S. infantis (1 strain); 2 strains could
not be identified. Of these, only S. mitis is capable
of causing VGS shock syndrome. Then, 5 of the 14
S. mitis (36 %) caused VGS shock syndrome.
The results of antimicrobial susceptibility tests for beta-
lactam agents are shown in Table 2. Among the 22 stored
VGS strains, the susceptibility rates for levofloxacin, cefe-
pime, piperacillin/tazobactam, meropenem, and vanco-
mycin were 0 %, 95 %, 100 %, 100 %, and 100 %,
respectively. Both the MIC50 of ceftazidime and MIC90 of
ceftazidime were higher than those of the APBL-VAs.
Additionally, only 1 of the 28 VGS strains (3.6 %) had a
penicillin MIC 2 μg/mL by Etest. The penicillin MICs for
the remaining VGS strains were <2 μg/mL. The penicillin
MICs for all the 6 VGS strains that cultured from blood
samples obtained from the recipients who were exposed
to a beta lactam in the previous 30 days (Table 1) were
ranged from 0.03 to 0.25 μg/mL (<2 μg/mL) by Etest.
Risk factors of the breakthrough VSB
To identify risk factors, the cumulative incidences of the
VSB among each group were compared (Additional
file.1). The recipients with the high risk hematological
disorders tended to have the VSB more frequent than
those with the standard risk (P = 0.11). However, no sig-
nificant risk factors were identified by univariate analysis
and multivariate analysis.
Therapeutic regimen
For empirical therapy, all 28 recipients received a
cefepime-based regimen (26 recipients) or a piperacillin/
tazobactam-based regimen (2 recipients) immediately
after withdrawing levofloxacin prophylaxis at the first
episode of FN. Four recipients received empirical vanco-
mycin administration. None of the recipients received
any empirical AGPA other than vancomycin.
Outcome of the breakthrough VSB in the evaluation
cohort
Among 19 recipients with mono VSB, 5 had VGS shock
syndrome (26 %). However, none of the recipients expe-
rienced ARDS. The crude 30-day mortality rate of the
VSB was 10.7 %. All 6 recipients who had septic shock
survived. In the 3 recipients who died, all the causative
VGS strains were susceptible to penicillin (MIC ≤
0.12 μg/mL).
Next, the characteristics and outcome of VSB in the
EC were evaluated. The EC consisted of 182 recipients,
since 2 recipients were excluded because they success-
fully achieved neutrophil engraftment without FN and
continued levofloxacin prophylaxis until neutrophil
engraftment. All the recipients were started on an
APBL-VA-based regimen at the onset of FN instead of
levofloxacin prophylaxis (Additional file.2). Thirteen re-
cipients (7.1 %) received additional empiric vancomycin
administration along with the APBL-based regimen. All
the recipients in the EC were divided into the VSB group
(28 patients), BSI without VSB group (54 patients), or
non-BSI group (100 patients). Some minor differences
were observed among the groups among the three
groups (Additional file.2). The causative organisms in
the BSI without VSB group are shown in Table 3.
Table 2 Antimicrobial (beta lactam) susceptibility of the breakthrough viridans group streptococcal strains




























0.5 1 2 4 8 16
Penicillin 28 ≤0.12 22 (79 %) >4 0 0.06 0.25 8 9 5 3 2 0 1 0 0 0
Ceftazidime 22 NA NA NA NA 0.5 2 5 7 7 1 0 2 0
Cefepime 22 ≤1 21 (95 %) >4 0 0.12 0.25 9 7 4 0 1 1 0 0 0
Meropenem 22 ≤0.5 22 (100 %) >1 0 ≤0.03 0.12 17 2 2 1 0 0
≤0.25/4 0.5/4 1/4 2/4 4/4 8/4 >16/4
Piperacillin/
tazobactam
22 ≤8/4 22 (100 %) >16/4 0 ≤0.25/4 ≤0.25/4 21 1 0 0 0 0 0
MIC minimum inhibitory concentration, CFPM cefepime, CAZ ceftazidim, NA not available
Kimura et al. BMC Infectious Diseases  (2016) 16:372 Page 5 of 10
Among the 54 recipients in the BSI without VSB group,
5 had co-infections. At the onset of FN, 1 recipient had
MRSA bacteremia and 1 had micafungin breakthrough
fungemia caused by Trichosporon asahii; however, none
of the recipients had VRE bacteremia or invasive asper-
gillosis. Clinicians ordered colonization screening tests
for 165 of the 182 recipients in the EC (91 %). The rate
of MRSA colonization and VRE colonization before
transplantation were 3 % (5/165), and 0 % (0/165), re-
spectively. The crude 30-day mortality rate after the on-
set of FN in the VSB group (10.7 %) was not
significantly different from that in the BSI without VSB
group (9.3 %) or the non-BSI group (7.0 %) (P = 0.77)
(Fig. 1). Also, the crude 60-day mortality rate in the VSB
group (10.7 %) was not significantly different from that
in the BSI without VSB group (16.7 %) or the non-BSI
group (14.0 %) (P = 0.81).
Risk factors for all-cause mortality up to 60 days following
allo-HSCT
Engraftment within 30 days following allo-HSCT, high
risk hematological diseases, and PH-allo-HSCT were
associated with the outcome up to 60 days following
allo-HSCT significantly in univariate analysis (Table 4).
While, VSB was not identified as the risk factor for the
mortality (P = 0.43). Then, engraftment within 30 days
was the independent factor that improved the survival sig-
nificantly (P = 0.0014) in the multivariate analysis
(Table 4).
Discussion
The high incidence of levofloxacin breakthrough VSB in
this study (15.2 %) was comparable to that of the previ-
ous study conducted in autologous peripheral blood
stem cell transplant setting (16.2 %) [6]. However, it was
higher than those in other studies that described levo-
floxacin breakthrough BSI in allo-HSCT setting [2, 3].
Fluoroquinolone prophylaxis had been approved for ap-
proximately 10 years at our hospital (Tosufloxacin
prophylaxis was used in our institute before January
2011 when the levofloxacin prophylaxis was started in-
stead of tosufloxacin prophylaxis.). The long use of the
fluoroquinolone prophylaxis might select VGS with di-
minished susceptibility to levofloxacin [6].
None of the 28 VGS strains assessed in this study were
susceptible to levofloxacin; in contrast, none of the
strains were resistant to penicillin based on the break-
point of CLSI (penicillin MIC ≥ 4 μg/mL) [21]. This low
penicillin resistant rate (0 %) was comparable to that re-
ported in Finland (2.3 %) [23]. In addition, the penicillin
MIC was 2 μg/mL for only 1 VGS strain, as assessed by
Etest (Table 2). Therefore, based on a previous report,
only 1 of the 28 VGS strains (3.6 %) was not considered
to have good susceptibility to APBL-VAs [11]. This rate
of 3.6 % for a penicillin MIC ≥ 2 μg/mL differs consider-
ably from the rates observed in North America and
Table 3 Causative organisms in the BSI without VSB group as
determined from blood cultures
No of strains
Gram positive cocci



















All the gram negative rods were resistant to levofloxacin except for
Helicobacter cinaedi and Campylobacter spp. The standard drug susceptibility
tests for Helicobacter cinaedi and Campylobacter spp. could not be performed
in our institute
BSI blood stream infection, VSB viridans streptococcal bacteremia, GPC gram-
positive coccus, GPR gram-positive rod
Fig. 1 The crude 30-day mortality after the onset of febrile neutro-
penia among the three groups
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Spain, which ranged from 17 % to 22 % [11, 24, 25].
Moreover, the susceptible rates of the APBL-VAs in this
study were over 95 %. In contrast, in vitro inferiority of
ceftazidime compared with the APBL-VAs was shown
(Table 2). A similar result was reported in the previous
study [24]. Accordingly, ceftazidime should probably not
be administrated as a first line empirical therapeutic
agent instead of the APBL-VAs when clinicians treat
levofloxacin breakthrough FN in a setting, where break-
through VSB is prevalent.
In the present study, 21 of the 24 recipients who did
not receive empiric vancomycin administration at the
first episode of FN were added vancomycin to APBL-
VA-based regimen immediately after a gram-positive
coccus was cultured from blood samples. This practice
is recommended by the IDSA guideline [1]. However, ac-
cording to the in vitro data described above, APBL-VA
mono therapy was optimal for almost all the VGSs
identified in our study. Thus, the empiric addition of
vancomycin to APBL-VA-based regimen would not typ-
ically be needed for treating mono VSB in our setting,
even when clinicians are awaiting the drug susceptibility
results of VGS strains.
Nosocomial VSB and receipt of a beta lactam antimicro-
bial in the previous 30 days were reported to be the useful
factors to predict VGS strains with a penicillin MIC ≥
2 μg/mL in the previous study that conducted in the set-
ting where beta-lactam non-susceptible VGS strains were
prevalent [11]. However, the positive predicted values of
them in the present study were only 3.7 % (1/28), and 0 %
(0/6), respectively. Hence, the predictive factors in the pre-
vious study would probably lead to overuse of unnecessary
empiric AGPAs administration in the settings where beta-
lactam non-susceptible VGS strains were rare.
In this study, both the crude 30-day mortality rate and
the crude 60-day mortality was 10.7 %. These were lower
Table 4 Risk factor for all-cause mortality up to 60 days following allogeneic hematopoietic stem cell transplantation
Univariate analysis
Pre-transplant factors Variables (Number) Mortality (%) P-value
Gender Male (119) 19.3 0.13
Female (65) 10.8
Age ≥60 (80) 18.8 0.42
<60 (104) 14.4
Diagnosis Myeloid malignacy (119) 16.8 0.83
non Myeloid malignancy (65) 15.4
Diseases risk High risk hematological diseases (151) 19.2 0.028
Standard risk hematological diseases (33) 3.03
PH of allo-HSCT Yes (25) 32.0 0.017
No (159) 13.8
Donor typre CBT (135) 19.3 0.076
non CBT (49) 8.16
Conditioning RIC(63) 22.3 0.11
MAC (121) 13.2
Time dependent factors
Viridans streptococcal bacteremia VSB (28) 10.7 0.43
non VSB (156) 17.3
Engraftment within Day30 Yes (161) 9.94 <0.001
No (23) 60.9
Multivariate analysis
Factors Hazard ratio 95 % confidence interval P-value
High risk hematological diseases 5.59 0.741–42.18 0.095
Prior history of allo-HSCT 2.09 0.919–4.740 0.079
CBT 1.66 0.569–4.839 0.35
Engraftment within Day30 0.22 0.087–0.558 0.0014
CBT cord blood transplantation, RIC reduced-intensity conditioning, MAC Myeloablative conditioning, allo-HSCT allogeneic hematopoietic stem cell transplantation,
VSB viridans streptococcal bacteremia, PH-allo-HSCT prior history of allogeneic hematopoietic stem cell transplantation
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than those reported in previous studies in the allo-
HSCT settings, which ranged from 21.9 to 24 % [13, 26].
In the previous study, seven of the 32 recipients with
VSB (21.9 %) died, at median of 26 days (range, 12–36
days) from VSB diagnosed because of ARDS and multi-
organ failure [13].
Further, both the crude 30-day mortality and the crude
60-day mortality after the onset of FN did not differ sig-
nificantly from those in the other two groups in this
study. Also, VSB was not a risk factor for all-cause mor-
tality up to 60 days following allo-HSCT (Table 4).
There was no VSB with ARDS in the present study, al-
though 3 % to 33 % of VSB caused ARDS during neutro-
penia in the previous studies [7]. It was probably one of
the reasons why the mortality of VSB in our study was
lower. S. mitis cluster2 identified by multilocus sequence
analysis is probably associated with ARDS because it
was reported to be associated with unexplained pulmon-
ary infiltrate during neutropenia [27]. There might be
few S. mitis cluster2 among all the 28 VGS strains in our
study. Additionally, the previous studies were not con-
ducted in the era of APBL-VAs, which may be one of
the reasons underlying the high mortality. However, the
exact reasons for the difference are unclear since the
drug susceptibility data from these studies are insuffi-
cient [13, 26]. In this context, breakthrough VSB is prob-
ably not a major cause of death in the present allo-
HSCT setting, where beta-lactam non-susceptible VGSs
and ARDS that associated with VSB are rare.
Some studies have recommended early or prophylactic
vancomycin administration to prevent VSB [5, 12, 13].
However, considering our results, clinicians should be
able to reduce that kind of AGPA administration in cer-
tain allo-HSCT settings, especially where beta-lactam
non-susceptible VGS is not prevalent, such as Japan and
Finland. Further epidemiological investigations regard-
ing VSB in various settings, including allo-HSCT settings
are needed.
Our study had some limitations. First, this study was
a single-center retrospective study. However, prospect-
ive, multicenter, or randomized trials to clarify appro-
priate antimicrobial usage for BSIs occurred in allo-
HSCT settings, such as VSB, are becoming increasingly
rare. Second, 182 of the 184 recipients (99 %) who
received levofloxacin prophylaxis had FN, although
levofloxacin prophylaxis has been reported to be effect-
ive in reducing FN incidence [28]. Fluoroquinolone
prophylaxis is an accepted protocol for neutropenic
patients with hematological malignancy and severe
neutropenia [1, 28, 29], although the limitations of
fluoroquinolone prophylaxis are also recognized [1, 30].
Therefore, analyzing the impact of levofloxacin break-
through infections is important for current allo-HSCT
settings. Third, susceptibility tests for APBL-VAs could
not be performed against all 28 VGS strains. However,
among the 22 stored VGS strains analyzed in this study,
the susceptibility rates for APBL-VAs were high
(Table 2). According to these data and the results of a
previous report, high susceptibility rates for APBL-VAs
against all the 28 strains are highly probable [11]. Forth,
the risk factor of the VSB was not identified. That
might be because the number of the recipients was not
enough. Among, 92 recipients who were checked their
oral conditions and had the data regarding them, the
cumulative incidence of the VSB in the recipients with
mucositis (21.3 %) tended to be higher than that in the
recipients without it (9.7 %) (P = 0.16). Mucositis might
be identified as the significant risk factor, if all the re-
cipients were checked their oral conditions.
Conclusions
In summary, the empiric addition of an AGPA, such as
vancomycin to an APBL-VA-based regimen would not
typically be needed for treating breakthrough VGS
strains in this setting. The indication of adding an em-
piric AGPA to APBL-VA based regimen for treating VSB
should depend on the local factors in each setting. In
addition, breakthrough VSB is probably not a major
cause of death in the allo-HSCT setting where the beta-
lactam non-susceptible VGS strains and the ARDS that
associated with VSB are rare.
Additional files
Additional file 1: The result of risk factor analysis for levofloxacin
breakthrough VSB among the 184 recipients. (DOCX 20 kb)
Additional file 2: Clinical characteristics of each of the three groups in
the evaluation cohort. (DOCX 47 kb)
Abbreviations
allo-HSCT, allogeneic hematopoietic stem cell transplant; BSI, blood stream
infection; VGS, viridans group streptococcus; FN, febrile neutropenia; IDSA,
Infectious Diseases Society of America; APBL, anti-pseudomonal beta-lactam;
APBL-VAs, APBLs with increased anti-VGS activity; AGPAs, anti-gram-positive
agents; MIC, minimum inhibitory concentration; VSB, viridans streptococcal
bacteraemia; ANC, absolute neutrophil count; MRSA, methicillin-resistant
Staphylococcus aureus; VRE, vancomycin-resistant enterococci; AML, acute
myeloid leukemia; MDS, myelodysplastic syndrome; PH-allo-HSCT, prior
history of allogeneic hematopoietic stem cell transplantation; ARDS, acute
respiratory distress syndrome; CLSI, Clinical Laboratory and Standards
Institute; EC, evaluation cohort
Acknowledgements
We thank the staff of the microbiology laboratory of Toranomon Hospital
and Dokkyo Medical University Hospital for performing identification and
drug susceptibility tests. We received helpful data regarding oral condition of
the recipients from Dr Mieko Yoshimura.
Funding
None.
Availability of data and materials
All data generated or analysed during this study are included in this
published article and its additional files (Additional files 1 and 2).
Kimura et al. BMC Infectious Diseases  (2016) 16:372 Page 8 of 10
Authors’ contributions
MK, HA and MA designed the study and collected data. MK, HA, HY and
YA-M analyzed the clinical data. MK and HA wrote the manuscript. AtY, YO,
and AH performed the identification and drug susceptibility testing for
viridans streptococcal strains. MY, DK, KK, AN, KaI, ShiT, GY, NU, KoI, AW, ShuT,
and AkY interpreted the results and reviewed the final draft of the manuscript.




The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Human Ethics Review Committee of
Toranomon Hospital. The committee approved this study without the need
for written informed consent because the data lacked patient identifiers.
Author details
1Department of Infectious Diseases, Toranomon Hospital, 2-2-2 Toranomon,
Minato-ku, Tokyo 105-8470, Japan. 2Department of Infection Control and
Clinical Laboratory Medicine, Dokkyo Medical University, Tochigi, Japan.
3Department of Hematology, Toranomon Hospital, Tokyo, Japan. 4Okinaka
Memorial Institute for Medical Research, Tokyo, Japan.
Received: 31 October 2015 Accepted: 5 July 2016
References
1. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al.
Clinical practice guideline for the use of antimicrobial agents in neutropenic
patients with cancer: 2010 update by the infectious disease society of
America. Clin Infect Dis. 2011;52(4):427–31.
2. Guthrie KA, Yong M, Frieze D, Corey L, Fredricks DN. The impact of a
change in antibacterial prophylaxis from ceftazidime to levofloxacin in
allogeneic hematopoietic cell transplantation. Bone Marrow Transplant.
2010;45(4):675–81.
3. Busca A, Cavecchia I, Locatelli F, D’Ardia S, De Rosa FG, Marmont F, et al.
Blood stream infections after allogeneic stem cell transplantation: a single-
center experience with the use of levofloxacin prophylaxis. Transpl Infect
Dis. 2012;14(1):40–8.
4. Blennow O, Liunqman P, Sparrelid E, Mattsson J, Remberger M. Incidence,
risk factors, and outcome of blood stream infections during the pre-
engraftment phase in 512 allogeneic hematopoietic stem cell
transplantations. Transpl Infect Dis. 2014;16(1):106–14.
5. Seo SK, Xiao K, Haung YT, Jongwutiwes U, Chung D, Maloy M, et al.
Impact of peri-transplant vancomycin and fluoroquinolone
administration on rates of bacteremia in allogeneic hematopoietic stem
cell transplant (HSCT) recipients: A 12-year single institution study. J
Infect. 2014;69(4):341–51.
6. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia
due to viridans group streptococci with diminished susceptibility to
levofloxacin among neutropenic patients receiving levofloxacin prophylaxis.
Clin Infect Dis. 2002;34(11):1469–74.
7. Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci
in neutropenic patients: a review. American J Med. 1994;97(3):256–64.
8. Gassas A, Grant R, Richardson S, et al. Predictors of viridans streptococcal
shock syndrome in bacteremic children with cancer and stem cell
transplant recipients. J Clin Oncol. 2004;22(7):1222–7.
9. Elting L, Bodey GP, Keefe BH. Septicemia and septic shock syndrome due to
viridans streptococci: a case–control study of predisposing factors. Clin
Infect Dis. 1992;14(6):1201–7.
10. Marron A, Carratala J, Gonzalez-Barca E, Fernandez-Sevilla A, Alcaide F,
Gudiol F. Serious complications of bacteremia caused by viridans
streptococci in neutropenic patients with cancer. Clin Infect Dis. 2000;
31(5):1126–30.
11. Shelburne 3rd SA, Lasky RE, Sahasrabhojane P, Tarrand JT, Rolston KV.
Development and validation of a clinical model to predict the presence
of β-lactam resistance in viridans group streptococci causing
bacteremia in neutropenic cancer patients. Clin Infect Dis. 2014;59(2):
223–30.
12. Arms da Cunha C, Weisdorf D, Shu XO, DeFor T, Pastor 3rd JD, Jhonson JR.
Early gram-positive bacteremia in BMT recipients: impact of three different
approaches to antimicrobial prophylaxis. Bone Marrow Transplant. 1998;
21(2):173–80.
13. Jaffe D, Jakubowski A, Sepkowitz K, Sebti R, Kiehn TE, Pamer E, et al.
Prevention of peritransplantation viridans streptococcal bacteremia with
early vancomycin administration: a single-center observational cohort study.
Clin Infect Dis. 2004;39(11):1625–32.
14. Masaoka T. Evidence-based recommendations for antimicrobial use in
febrile neutropenia in Japan: Executive Summary. Clin Infect Dis. 2004;15
Suppl 1:S49–52.
15. Yamamoto H, Uchida N, Matsuno N, Ota H, Kageyama K, Wada S, et al. Anti-
HLA antibodies other than against HLA-A, B, DRB1 adversely affect
engraftment and nonrelapse mortality in HLA-mismatched single cord
blood transplantation: possible implications of unrecognized donor-specific
antibodies. Biol Blood Marrow Transplant. 2014;20(10):1634–40.
16. Giral S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al.
Reduced-intensity conditioning regimen workshop: defining the dose
spectrum. Report of a workshop convened by the center for
international blood and marrow transplant research. Biol Blood Marrow
Transplant. 2009;15(3):367–9.
17. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM,
et al. Surviving sepsis campaign: international guidelines for
management of severe sepsis and septic shock: 2012. Crit Care Med.
2013;41(2):580–637.
18. Definition Task Force ARDS, Ranieri VM, Rubenfeld GD, Thompson BT,
Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress
syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–33.
19. Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al.
European Organization for Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group; National Institute of Allergy and
Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus
Group. Revised difinitions of invasive fungal disease from the European
Organization for Research and Treatment of Cancer/Invasive Fungal
Infectious Cooperative Group and National Institute of Allergy and
Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus
Group. Clin Infect Dis. 2008;46(12):1813–21.
20. Hoshino T, Fujiwara T, Kilian M. Use of phylogenetic and phenotypic
analyses to identify nonhemolytic streptococci isolated from bacteremic
patients. J Clin Microbiol. 2005;43(12):6073–85.
21. Clinical and Laboratory Standard Institute. Performance standards for
antimicrobial susceptibility testing. Twenty-second informational
supplement. Wayne: Document M100-S22 CLSI; 2012.
22. Kanda Y. Investigation of the freely available east-to-use software ‘EZR’ for
medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
23. Lindgren M, Jalava J, Rantakokko-Jalava K, Meurman O. In vitro susceptibility
of viridans group streptococci isolated from blood in southwest Finland in
1993–2004. Scand J Infect Dis. 2007;39(6–7):508–13.
24. Paulus S, Dobson S, Rassekh S, Blondel-Hill E. In vitro inferiority of
ceftazidime compared with other beta-lactams for viridans group
Streptococcus bacteremia in pediatric oncology patients: implications for
antibiotics choices. J Pediatr Hematol Oncol. 2009;31(4):267–9.
25. Marron A, Carratala J, Alcaide F, Fernandez-Sevilla A, Gudiol F. High rates of
resistance to cephalosporins among viridans-group streptococci causing
bacteremia in neutropenic cancer patients. J Antimicrob Chemother. 2001;
47(1):87–91.
26. Almyroudis NG, Fuller A, Jakubowski A. Pre- and post-engraftment
bloodstream infection rates and associated mortality in allogeneic
hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005;
7(1):11–7.
27. Shelburn SA, Sahasrabhojane P, Saldana M, Yao H, Su X, Horstmann N, et al.
Streptococcus mitis strains causing severe clinical diseases in cancer
patients. Emerg Infect Dis. 2014;20(5):762–71.
28. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G,
et al. Levofloxacin to prevent bacterial infection in patients in patients with
cancer and neutropenia. N Engl J Med. 2005;353(10):977–87.
Kimura et al. BMC Infectious Diseases  (2016) 16:372 Page 9 of 10
29. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic
prophylaxis reduces mortality in neutropenic patients. Ann Intern Med.
2005;142(12 Pt 1):979–95.
30. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, et al.
Fluoroquinolone resistance of Escherichia coli at a cancer center:
epidemiologic evolution effects of discontinuing prophylactic
fluoroquinolone use in neutropenoic patients with leukemia. Eur J Clin
microbial Infect Dis. 2005;24(2):111–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kimura et al. BMC Infectious Diseases  (2016) 16:372 Page 10 of 10
